Alicia Cabrera, MD
Neurology · Altamonte Springs, FLNPI 1770789000
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $31,599 of the $39,314 with a category attached, or 80.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,481 payments — averaging $26.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$5K
- AbbVie$4K
- Novartis$3K
- Sanofi$3K
- EMD Serono, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- plus $21K from 54 others
Across 252 payments — averaging $36,842 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5M
- Eli Lilly$1.2M
- E.r. Squibb & Sons, L.L.C.$1M
- Sanofi$735K
- Genentech, Inc.$672K
- UCB SA$310K
- plus $429K from 8 others
What the payments were for
- Consulting fees$4,74712%
- Speaking & faculty fees$8182%
- Travel & lodging$1,9895%
- Food & beverage$31,59980%
- Education$1620%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,314 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 72 | $660,949 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 55 | $426,302 |
| IngrezzaValbenazine Tosylate | 41 | $371,393 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 11 | $342,214 |
| UbrelvyUbrogepant | 223 | $339,410 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 16 | $317,826 |
| SolirisEculizumab | 12 | $313,104 |
| Nurtec OdtRimegepant Sulfate | 178 | $294,892 |
| Austedo XrDeutetrabenazine | 31 | $259,236 |
| QuliptaAtogepant | 165 | $193,644 |
| Kesimpta PenOfatumumab | 19 | $172,230 |
| VumerityDiroximel Fumarate | 27 | $161,031 |
| BotoxOnabotulinumtoxina | 69 | $71,980 |
| Aimovig AutoinjectorErenumab-Aooe | 72 | $57,147 |
| RytaryCarbidopa/Levodopa | 46 | $55,288 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $175 | $660,94972 claims |
| AbbVieUbrelvy, Qulipta, Botox, Namzaric | $4,089 | $627,912472 claims |
| Grifols USA, LLCGamunex-C | $152 | $426,30255 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,483 | $371,39341 claims |
| PfizerNurtec Odt, Eliquis, Zavzpret | $1,080 | $338,158224 claims |
| CSL BehringPrivigen | $53 | $317,82616 claims |
| AstraZenecaSoliris | $767 | $313,10412 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,418 | $259,23631 claims |
| BiogenVumerity | $5,162 | $161,03127 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $498 | $77,531258 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,359 | $54,94511 claims |
| UCB, Inc.Neupro | $731 | $35,34934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Altamonte Springs
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.